Dordaviprone

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Glioma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Glioma
NCT05476939 · Gustave Roussy, Cancer Campus, Grand Paris
2022-09-29 – 2031-09 · Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
What this study did
NCT05580562 · Jazz Pharmaceuticals
2023-01-23 – 2028-06 · H3 K27M, Glioma
What this study did
Phase 2 (11)
Glioma
NCT05009992 · University of California, San Francisco
2021-10-20 – 2029-06-30 · Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
What this study did
Other / comorbidity
NCT04055649 · Ira Winer
2020-01-21 – 2027-05-28 · Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
What this study did
NCT06012929 · University of Nebraska
2026-12 – 2027-04 · Meningioma, Refractory Meningioma, Relapsed Meningioma
What this study did
NCT04629209 · Masonic Cancer Center, University of Minnesota
2024-06-28 – 2025-06-30 · Glioblastoma
What this study did
NCT03034200 · Peter Anderson
2017-08-02 – 2023-05-19 · Recurrent Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor
What this study did
NCT03485729 · Jazz Pharmaceuticals
2018-03-21 – 2023-01-19 · Endometrial Cancer Recurrent
What this study did
NCT03394027 · National Cancer Institute (NCI)
2018-01-17 – 2021-10-07 · Triple Negative Breast Cancer, Endometrial Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer
What this study did
NCT03733119 · University of Wisconsin, Madison
2018-11-13 – 2021-02-13 · Triple Negative Breast Cancer
What this study did
NCT03099499 · Fox Chase Cancer Center
2017-06-08 – 2020-09-09 · Endometrial Cancer
What this study did
Phase 1/2 (6)
Other / comorbidity
NCT02392572 · M.D. Anderson Cancer Center
2015-11-03 – 2026-08-14 · Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
What this study did
NCT03791398 · Brown University
2019-11-15 – 2021-08-05 · Metastatic Colorectal Cancer
What this study did
NCT02420795 · M.D. Anderson Cancer Center
2015-11-03 – 2020-11-16 · Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Splenic Mantle Cell Lymphoma
What this study did
NCT03492138 · Ajai Chari
2018-03-26 – 2020-01-14 · Multiple Myeloma
What this study did
NCT02863991 · Jazz Pharmaceuticals
2017-04-19 – 2019-12-16 · Multiple Myeloma
What this study did
NCT02038699 · Jazz Pharmaceuticals
2014-01 – 2016-12 · Advanced Glioblastoma, Advanced Colorectal Cancer, Advanced Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
What this study did
Phase 1 (8)
Glioma
Other / comorbidity
NCT05630794 · National Cancer Institute (NCI)
2025-10-06 – 2029-05-01 · Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
What this study did
NCT05542407 · UNC Lineberger Comprehensive Cancer Center
2023-10-23 – 2028-07-31 · Endometrial Cancer, Metastasis, Endometrioid Endometrial Cancer, Carcinosarcoma, Serous Adenocarcinoma of Endometrium (Diagnosis), Clear Cell Endometrial Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
What this study did
NCT04854044 · Jonsson Comprehensive Cancer Center
2021-05-01 – 2026-07-01 · Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma
What this study did
NCT03932643 · University of Nebraska
2019-07-30 – 2025-03-27 · Acute Myeloid Leukemia, Myelodysplastic Syndromes
What this study did
NCT02609230 · Fox Chase Cancer Center
2015-11-05 – 2020-03-26 · Advanced Solid Tumors, Multiple Myeloma
What this study did
NCT02250781 · Rutgers, The State University of New Jersey
2015-01-12 – 2018-10-25 · Solid Tumors
What this study did
NCT02324621 · Rutgers, The State University of New Jersey
2015-02-20 – 2018-10-23 · Unspecified Adult Solid Tumor
What this study did

Competitive landscape

This drug's own stage for Glioma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dordaviprone: this drugApprovedSmall moleculeMitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptorWeak signalNo reviewed efficacy summary in this indication
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)not yet gradedNo reviewed efficacy summary in this indication
TemozolomideApprovedSmall moleculeDNA alkylation (O6-guanine)Partial signal
NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results).
TovorafenibApprovedSmall moleculeKinase InhibitorWeak signalNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
LuvometinibPhase 3Small moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
SafusidenibPhase 3Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
Abemaciclib (Verzenio)Phase 2Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
OlutasidenibPhase 2Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
CrelosidenibPhase 1Small moleculeMutant IDH1 and IDH2not yet gradedNo reviewed efficacy summary in this indication
VebreltinibPhase 1Small moleculeMETnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dordaviprone to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
May 2027 (1)
Phase 2Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma …Recruiting
Est. primary completion 2027-05-28 · NCT04055649 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2GliomaRecruiting
Est. primary completion 2027-12-31 · NCT05009992 · CT.gov ↗
What to watch
2028 (4)
February 2028 (1)
Phase 1Endometrial Cancer, Metastasis, Endometrioid Endometrial Cancer, Carcinosarcoma, Serous Adenocarcinoma of Endometrium (Diagnosis) …Recruiting
Est. primary completion 2028-02-21 · NCT05542407 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3GliomaRecruiting
Est. primary completion 2028-06 · NCT05580562 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous PolypsRecruiting
Est. primary completion 2028-07-01 · NCT05630794 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3GliomaRecruiting
Est. primary completion 2028-09 · NCT05476939 · CT.gov ↗
What to watch

See the full readout calendar ↗